Novartis Ag

Ciba-geigy Corporation

Speedel Pharma Ag

Speedel Experimenta Ag

The Medicines Company (leipzig) Gmbh

Ciba Specialty Chemicals Corporation

Novartis Corporation

Solvias Ag

Novartis Pharma Ag

The Medicines Company

Peter Herold

Stefan Stutz

Vincenzo Tschinke

Robert Mah

Aleksandar Stojanovic

Christiane Marti

Michael Siegfried Quirmbach

Stjepan Jelakovic

Dirk Behnke

Nathalie Jotterand

Pascal Rigollier

Nissim Claude Cohen

Walter Schilling

Yasuchika Yamaguchi

Richard Goschke

Christoph Schumacher

Jurgen Klaus Maibaum

Bibia Bennacer

Felix Spindler

Andrea Schweinitz

Adriano Indolese

Claudia Reichelt

Alexander Schulze

Mohammed Daghish

Friedrich-Alexander Ludwig

J Urgen Maibaum

Richard G Oschke

Guido Bold

Rudolf Duthaler

Robert W Lang

Konrad Oertle

Martin Riediker

Christof Angst

Walter Weissensteiner

Thomas Sturm

Martin Studer

Adel Rafai Far

Isabelle Lyothier

Frank Peter Hollinger

Zenon D Konteatis

Ting Kang

Jennifer Lee Ludington

Stefan Burckhardt

Michael Quirmbach

Frank Hollinger

Jennifer L Ludington

The invention provides compounds that are effective as inhibitors of human plasmin and plasma kallikrein, and that are useful for the prevention of blood loss and as components of fibrin adhesives. The invention further provides methods of making and using the compounds.

Trypsin-like serine protease inhibitors, and their preparation and use

The application relates to novel heterocyclic compounds of the general formula (I) in which R, R, R, X, Y, Z and n have the meanings defined in the description, to a process for their preparation and to the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors. 

Tetrahydro-imidazo [1,5-A] pyridyin derivatives as aldosterone synthase inhibitors

The invention provides methods of making and using compounds of the formula: or a pharmaceutically acceptable salt thereof; wherein n is an integer between 1 and 2 inclusively; m is an integer between 0 and 2 inclusively; X is selected from the group consisting of CH or N; Ris selected from the group consisting of &#x2014;CHNH, and Ris selected from the group consisting of &#x2014;H, &#x2014;OH, &#x2014;NHand acetyl; Ris selected from the group consisting of &#x2014;H, benzyloxycarbonyl and benzylsulfonyl; and Ris selected from the group consisting of &#x2014;OH, wherein p is an integer between 0 and 2 inclusively, Y is selected from the group consisting of &#x2014;O&#x2014;, &#x2014;S&#x2014;, &#x2014;S(&#x2550;O)&#x2014;, &#x2014;SO&#x2014;, methylene, &#x2014;CH(OH)&#x2014;, &#x2014;CH(NH)&#x2014;, &#x2014;CH(CH&#x2014;OH)&#x2014;, &#x2014;CH(CH&#x2014;NH)&#x2014; or &#x2014;N(R)&#x2014;, Ris selected from the group consisting of &#x2014;H or a simple (C-C) alkyl and Ris selected from the group consisting of &#x2014;H, a simple (C-C) alkyl or a simple (C-C) acyl. These compounds are useful as anticoagulant agents as a result of their selective dual inhibition of thrombin and prothrombinase.

Trypsin-like serine protease inhibitors, their preparation and use as selective inhibitors of the clotting factors IIa and Xa

The patent application relates to new heterocyclic compounds of the general formula (I), in which R, R, R, Q, T, n and p have the definitions elucidated in more detail in the description, to a process for preparing them and to the use of these compounds as medicaments, particularly as aldosterone synthase inhibitors. 

Heterocyclic spiro-compounds

Heterocyclic compounds of the general formula (I) are provided in which R, R, R, R, Rand n have the definitions elucidated in more detail in the description, to a process for preparing them and to the use of these compounds as medicaments, particularly as aldostereone synthase inhibitors, 

Bis-heterocyclic imidazolyl compounds

Heterocyclic compounds of the formula (I) and salts, preferably pharmaceutically acceptable salts thereof, are provided in which R, R, R, Q, m and n have the meanings explained in detail in the description. Also provided are a process for their preparation and the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors. 

Imidazo compounds

Novel heterocyclic compounds of the general formula (I) and salts, preferably pharmaceutically acceptable salts, thereof, in which R, R, R', Q, m and n have the meanings explained in detail in the description, a process for their preparation and the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors. 

Spiro-imidazo compounds

The application relates to novel heterocyclic compounds of the general formula (I) and salts, preferable pharmaceutically acceptable salts, thereof, in which R, R, R, R, Q, m and n have the meanings explained in detail in the description, a process for their preparation and the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors.

Condensed imidazole derivatives as aldosterone synthase inhibitors

Compounds of the general formula (I) or its salt or a compound in which one or more atoms are replaced by their stable, nonradio-active isotopes, in particular its pharmaceutically acceptable salt; in which X is &#x2014;CH&#x2014;; R is a mono- to tetra-substituted, mono- or bicyclic, unsaturated heterocyclic radical having 1 to 4 nitrogen atoms, Ris Calkyl or Ccycloalkyl; Ris independently of one another H, Calkyl, Calkoxycarbonyl or Calkanoyl; Ris Calkenyl, Calkyl, unsubstituted or substituted aryl-Calkyl or Ccycloalkyl; Ris -L-R; L is Calkylene which is optionally substituted by 1-4 halogen, or a linker: formula (II) n=0, 1 or 2; m=0 or 1; Ris a radical composed of 2 cyclic systems selected from bicyclo[x.y.z]alkyl, spiro[o.p]alkyl, mono- or bioxabicyclo[x.y.z]alkyl or mono- or bioxaspiro[o.p]alkyl, all of which may be substituted by 1-3 substituents selected from Calkyl, Calkoxy, cyano, halogen, Calkoxy-Calkyl, hydroxy-Calkyl or dialkylamino, or if m=0: is also saturated Cheterocyclyl which comprises 1-2 oxygen atoms, substituted by 1-3 substituents selected from Calkyl, Calkoxy, cyano, halogen, Calkoxy-Calkyl, hydroxy-Calkyl or dialkylamino, or if m=1: is also saturated Cheterocyclyl which comprises 1-2 oxygen atoms, optionally substituted by 1-3 substituents selected from Calkyl, Calkoxy, cyano, halogen, C-alkoxy-Calkyl, hydroxy-Calkyl or dialkylamino; have renin-inhibiting properties and can be used as medicines for the treatment of hypertension. 

5-amino-4-hydroxy-7-(imidazo [1,2-A] pyridin-6-ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension

The patent application relates to new heterocyclic compounds of the general formula (I) in which A, R, R, R, U, V, W, X, Y, Z, n and p have the definitions elucidated in more detail in the description, to a process for preparing them and to the use of these compounds as medicaments, particularly as aldosterone synthase inhibitors. 

Heterocyclic spiro-compounds as aldosterone synthase inhibitors

The patent application relates to new heterocyclic compounds of the general formula (I) in which R, R, R, W, X, Y, Z and n have the definitions elucidated in more detail in the description, to a process for preparing them and to the use of these compounds as medicaments, particularly as aldosterone synthase inhibitors. 

Compounds of the general formula (formula I) in which the meanings of the substituents R1 to R6 are as indicated in claim, have renin-inhibiting properties and can be used as medicines. 

Alcanoic acid amides substituted by saturated O-heterocycles

The present invention relates to compounds of the general formula (I) and the salts thereof, preferably the pharmaceutically acceptable salts thereof; in which R has the meaning explained in the description, a process for their preparation and the use of these compounds as medicines, especially as renin inhibitors. 

Substituted piperidines as renin inhibitors

Growing community of inventors

Basel, Switzerland

Peter Herold